PURPOSE OF REVIEW: Triple-negative breast cancer (TNBC) is clinically characterized by the lack of expression of the estrogen receptor/progesterone receptor and the human epidermal growth factor receptor 2. It is highly heterogeneous and exhibits considerable overlap with basal-like and BRCA-related breast cancers. Constituting 15-20% of breast cancers, TNBC exhibits an aggressive phenotype with a poor prognosis. This review summarizes recent progress and studies in TNBC and discusses some of the ongoing clinical trials and emerging therapies for the treatment of TNBC. RECENT FINDINGS: Conventional cytotoxic chemotherapy and DNA damaging agents continue to be the mainstay for treatment of this disease. The use of targeted agents such as bevacizumab, epidermal growth factor receptor and polyadenosine diphosphate-ribose polymerase inhibitors have led to conflicting results. However, recent research has prompted evaluation of additional drugs targeting multiple signaling pathways and epigenetic modifications for the treatment of this disease. SUMMARY: TNBC remains a challenging disease to treat with recent trials having demonstrated only modest improvements in outcomes. Increased understanding of the heterogeneity of this complex subtype may help tailor therapies to specific patient subgroups.
PURPOSE OF REVIEW: Triple-negative breast cancer (TNBC) is clinically characterized by the lack of expression of the estrogen receptor/progesterone receptor and the humanepidermal growth factor receptor 2. It is highly heterogeneous and exhibits considerable overlap with basal-like and BRCA-related breast cancers. Constituting 15-20% of breast cancers, TNBC exhibits an aggressive phenotype with a poor prognosis. This review summarizes recent progress and studies in TNBC and discusses some of the ongoing clinical trials and emerging therapies for the treatment of TNBC. RECENT FINDINGS: Conventional cytotoxic chemotherapy and DNA damaging agents continue to be the mainstay for treatment of this disease. The use of targeted agents such as bevacizumab, epidermal growth factor receptor and polyadenosine diphosphate-ribose polymerase inhibitors have led to conflicting results. However, recent research has prompted evaluation of additional drugs targeting multiple signaling pathways and epigenetic modifications for the treatment of this disease. SUMMARY: TNBC remains a challenging disease to treat with recent trials having demonstrated only modest improvements in outcomes. Increased understanding of the heterogeneity of this complex subtype may help tailor therapies to specific patient subgroups.
Authors: Cheng-Chieh Yang; Adam LaBaff; Yongkun Wei; Lei Nie; Weiya Xia; Longfei Huo; Hirohito Yamaguchi; Yi-Hsin Hsu; Jennifer L Hsu; Dongping Liu; Jingyu Lang; Yi Du; Huang-Chun Lien; Long-Yuan Li; Rong Deng; Li-Chuan Chan; Jun Yao; Celina G Kleer; Gabriel N Hortobagyi; Mien-Chie Hung Journal: Am J Transl Res Date: 2015-06-15 Impact factor: 4.060
Authors: Jenny G Parvani; Maneesh D Gujrati; Margaret A Mack; William P Schiemann; Zheng-Rong Lu Journal: Cancer Res Date: 2015-04-09 Impact factor: 12.701
Authors: Mario Niepel; Marc Hafner; Emily A Pace; Mirra Chung; Diana H Chai; Lili Zhou; Birgit Schoeberl; Peter K Sorger Journal: Sci Signal Date: 2013-09-24 Impact factor: 8.192
Authors: X Wang; J Ren; J Zhang; Y Yan; N Jiang; J Yu; L Di; G Song; L Che; J Jia; X Zhou; H Yang; H K Lyerly Journal: Clin Transl Oncol Date: 2015-08-13 Impact factor: 3.405
Authors: Matthew D Burstein; Anna Tsimelzon; Graham M Poage; Kyle R Covington; Alejandro Contreras; Suzanne A W Fuqua; Michelle I Savage; C Kent Osborne; Susan G Hilsenbeck; Jenny C Chang; Gordon B Mills; Ching C Lau; Powel H Brown Journal: Clin Cancer Res Date: 2014-09-10 Impact factor: 12.531
Authors: Sara Movassaghian; Yuran Xie; Claudia Hildebrandt; Rayna Rosati; Ying Li; Na Hyung Kim; Denise S Conti; Sandro R P da Rocha; Zeng-Quan Yang; Olivia M Merkel Journal: Mol Pharm Date: 2016-06-27 Impact factor: 4.939